Hamostaseologie最新文献_第3页

Update on Tissue Factor Detection in Blood in 2024: A Narrative Review. 2024 年血液中组织因子检测的最新进展：叙述性综述。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2024-10-01 Epub Date: 2024-10-23 DOI: 10.1055/a-2381-6854

Amandine Bonifay, Sylvie Cointe, Léa Plantureux, Romaric Lacroix, Françoise Dignat-George

{"title":"Update on Tissue Factor Detection in Blood in 2024: A Narrative Review.","authors":"Amandine Bonifay, Sylvie Cointe, Léa Plantureux, Romaric Lacroix, Françoise Dignat-George","doi":"10.1055/a-2381-6854","DOIUrl":"https://doi.org/10.1055/a-2381-6854","url":null,"abstract":"Tissue factor (TF) is a transmembrane protein essential for hemostasis. Different forms of active TF circulate in the blood, either as a component of blood cells and extracellular vesicles (EVs) or as a soluble plasma protein. Accumulating experimental and clinical evidence suggests that TF plays an important role in thrombosis. Many in-house and commercially available assays have been developed to measure TF-dependent procoagulant activity or antigen in blood and have shown promising results for the prediction of disease outcomes or the occurrence of thrombosis events in diseases such as cancer or infectious coagulopathies. This review addresses the different assays that have been published for measuring circulating TF antigen and/or activity in whole blood, cell-free plasma, and EVs and discusses the main preanalytical and analytical parameters that impact results and their interpretation, highlighting their strengths and limitations. In the recent decade, EVTF assays have been significantly developed. Among them, functional assays that use a blocking anti-TF antibody or immunocapture to measure EVTF activity have higher specificity and sensitivity than antigen assays. However, there is still a high variability between assays. Standardization and automatization are prerequisites for the measurement of EVTF in clinical laboratories.","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":"44 5","pages":"368-376"},"PeriodicalIF":2.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142513326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Arterial and Venous Thromboembolic Complications in 832 Patients with BCR-ABL-Negative Myeloproliferative Neoplasms. 832例BCR-ABL阴性骨髓增生性肿瘤患者的动脉和静脉血栓栓塞并发症。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2024-10-01 Epub Date: 2023-10-09 DOI: 10.1055/a-2159-8767

Kai Wille, Eva Deventer, Parvis Sadjadian, Tatjana Becker, Vera Kolatzki, Karlo Hünerbein, Raphael Meixner, Marina Jiménez-Muñoz, Christiane Fuchs, Martin Griesshammer

{"title":"Arterial and Venous Thromboembolic Complications in 832 Patients with BCR-ABL-Negative Myeloproliferative Neoplasms.","authors":"Kai Wille, Eva Deventer, Parvis Sadjadian, Tatjana Becker, Vera Kolatzki, Karlo Hünerbein, Raphael Meixner, Marina Jiménez-Muñoz, Christiane Fuchs, Martin Griesshammer","doi":"10.1055/a-2159-8767","DOIUrl":"10.1055/a-2159-8767","url":null,"abstract":"Arterial (ATE) and venous (VTE) thromboembolic complications are common causes of morbidity and mortality in BCR-ABL-negative myeloproliferative neoplasms (MPNs). However, there are few studies that include all MPN subtypes and focus on both MPN-associated ATE and VTE. In our single-center retrospective study of 832 MPN patients, a total of 180 first thromboembolic events occurred during a median follow-up of 6.6 years (range: 0-37.6 years), of which 105 were VTE and 75 were ATE. The probability of a vascular event at the end of the follow-up period was 36.2%, and the incidence rate for all first ATE/VTE was 2.43% patient/year. The most frequent VTE localizations were deep vein thrombosis with or without pulmonary embolism (incidence rate: 0.59% patient/year), while strokes were the most frequent ATE with an incidence rate of 0.32% patient/year. When comparing the group of patients with ATE/VTE (n = 180) and the group without such an event (n = 652) using multivariate Cox regression analyses, patients with polycythemia vera (hazard ratio [HR]: 1.660; [95% confidence interval [CI] 1.206, 2.286]) had a significantly higher risk of a thromboembolic event than the other MPN subtypes. In contrast, patients with a CALR mutation had a significantly lower risk of thromboembolism compared with JAK2-mutated MPN patients (HR: 0.346; [95% CI: 0.172, 0.699]). In summary, a high incidence of MPN-associated VTE and ATE was observed in our retrospective study. While PV patients or generally JAK2-mutated MPN patients had a significantly increased risk of such vascular events, this risk was reduced in CALR-mutated MPN patients.","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":"386-392"},"PeriodicalIF":2.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41184199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

iTTP in der Schwangerschaft: Erfolgreiche Behandlung mit Caplacizumab. 妊娠期 iTTP：卡普珠单抗的成功治疗。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2024-10-01 Epub Date: 2024-10-23 DOI: 10.1055/s-0044-1791987

引用次数: 0

Medizinforschungsgesetz, Apothekenreform-Gesetz, Telemedizin Blutspende-Verordnung, Erweiterung der Dokumentationspflichten im Deutschen Hämophilieregister (DHR). 医学研究法》、《药房改革法》、《远程医疗献血条例》、《德国血友病登记册》（DHR）文件义务的扩展。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2024-10-01 Epub Date: 2024-10-23 DOI: 10.1055/a-2316-4096

Jürgen Koscielny, Günther Kappert, Christoph Sucker

引用次数: 0

Acid Treatment of FVIII-Containing Plasma Samples Unmasks a Broad Spectrum of FVIII-Specific Antibodies in ELISA. 对含 FVIII 的血浆样本进行酸处理可在 ELISA 检测中检测出广泛的 FVIII 特异性抗体。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2024-10-01 Epub Date: 2024-07-15 DOI: 10.1055/a-2329-1781

Anja Schmidt, Diana Stichel, Emilia Salzmann-Manrique, Christoph Königs

引用次数: 0

Komplementdysregulation als Biomarker für Post Covid. 补体失调是后 Covid 的生物标志物。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2024-10-01 Epub Date: 2024-10-23 DOI: 10.1055/s-0044-1791988

引用次数: 0

Utility of Global Hemostatic Assays in Patients with Bleeding Disorders of Unknown Cause. 全球止血检测对不明原因出血患者的实用性。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2024-10-01 Epub Date: 2024-07-01 DOI: 10.1055/a-2330-9112

Dino Mehic, Alice Assinger, Johanna Gebhart

{"title":"Utility of Global Hemostatic Assays in Patients with Bleeding Disorders of Unknown Cause.","authors":"Dino Mehic, Alice Assinger, Johanna Gebhart","doi":"10.1055/a-2330-9112","DOIUrl":"10.1055/a-2330-9112","url":null,"abstract":"Bleeding disorder of unknown cause (BDUC) is a diagnosis of exclusion after exhaustive evaluation of plasmatic coagulation and platelet function. This review explores the utility of global hemostatic assays as confirmatory tests and in elucidating the pathophysiology of BDUC. Unlike traditional hemostatic tests that focus on coagulation factors, global assays are conducted both in plasma and also whole blood. These assays provide a more comprehensive understanding of the cell-based model of coagulation, aid in the identification of plasmatic factor abnormalities that may reduce hemostatic capacity, and allow for the assessment of impaired platelet-endothelial interactions under shear stress, as well as hyperfibrinolytic states. While clinical tests such as skin bleeding time and global assays such as PFA-100 exhibit limited diagnostic capacity, the role of viscoelastic testing in identifying hemostatic dysfunction in patients with BDUC remains unclear. Thrombin generation assays have shown variable results in BDUC patients; some studies demonstrate differences compared with healthy controls or reference values, whereas others question its clinical utility. Fibrinolysis assessment in vitro remains challenging, with studies employing euglobulin clot lysis time, plasma clot lysis time, and fluorogenic plasmin generation yielding inconclusive or conflicting results. Notably, recent studies suggest that microfluidic analysis unveils shear-dependent platelet function defects in BDUC patients, undetected by conventional platelet function assays. Overall, global assays might be helpful for exploring underlying hemostatic impairments, when conventional hemostatic laboratory tests yield no results. However, due to limited data and/or discrepant results, further research is needed to evaluate the utility of global assays as screening tools.","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":"358-367"},"PeriodicalIF":2.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141478019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Be Curious. Try New Things. 要有好奇心。尝试新事物。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2024-10-01 Epub Date: 2024-10-28 DOI: 10.1055/a-2316-4116

Johannes Thaler

引用次数: 0

Die Gesellschaft für Thrombose- und Hämostaseforschung e.V. informiert. 血栓与止血研究学会通报。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2024-10-01 Epub Date: 2024-10-23 DOI: 10.1055/s-0044-1791986

引用次数: 0

Investigations on the Hemostatic Potential of Physiological Body Fluids. 关于生理体液止血潜能的研究。

IF 2.7 4区医学